EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection

Neha Thakre, Denise Beck, Ahmed M Saeed, Doerthe Eckert, Mong-Jen Chen, Wei Liu, Hoi Kei Lon, Nael M Mostafa, Sven Mensing

Clinical Pharmacokinetics · 2026-07 · 65 (7) · 1061-1072

DOI: 10.1007/s40262-026-01637-1 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 26.05.2026. Verfasst von Neha Thakre und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Knollstraße 50, 67061, Ludwigshafen am Rhein, Germany. Hauptthemen laut MEDLINE: Antiviral Agents, Benzimidazoles, Hepatitis C, Chronic, Pyrrolidines. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsBenzimidazolesHepatitis C, ChronicPyrrolidinesQuinoxalinesSulfonamidesAdolescentChildChild, PreschoolFemaleHumansMaleAminoisobutyric AcidsCyclopropanesGenotypeHepacivirusLactams, MacrocyclicLeucineModels, BiologicalProlineDrug Combinations

Substanzen

Aminoisobutyric AcidsAntiviral AgentsBenzimidazolesCyclopropanesglecaprevirglecaprevir and pibrentasvirLactams, MacrocyclicLeucinepibrentasvirProline

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Knollstraße 50, 67061, Ludwigshafen am Rhein, Germany.
  • Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Knollstraße 50, 67061, Ludwigshafen am Rhein, Germany. denise.beck@abbvie.com.
  • Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA.

Förderung

  • AbbVie

Zitieren

APA

Thakre, N., Beck, D., Saeed, A. M., Eckert, D., Chen, M. J., Liu, W., Lon, H. K., Mostafa, N. M., & Mensing, S. (2026). Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection. Clinical Pharmacokinetics, 65(7), 1061-1072. https://doi.org/10.1007/s40262-026-01637-1

Vancouver

Thakre N, Beck D, Saeed AM, Eckert D, Chen MJ, Liu W, et al. Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection. Clinical Pharmacokinetics. 2026;65(7):1061-1072. doi:10.1007/s40262-026-01637-1

BibTeX
@article{Thakre2026,
  author = {Thakre, Neha and Beck, Denise and Saeed, Ahmed M and Eckert, Doerthe and Chen, Mong-Jen and Liu, Wei and Lon, Hoi Kei and Mostafa, Nael M and Mensing, Sven},
  title = {Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {7},
  pages = {1061--1072},
  doi = {10.1007/s40262-026-01637-1}
}
Kostenlos starten →